Fischer Medical Ventures share price today

Fischer Medical Ventures Ltd's share price was ₹25.23 at the close on 4 November 2026. It has been falling for 48 weeks. That is 37.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹25 and ₹93, and at that close it sat 1% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Fischer Medical Ventures Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 9 weeks running.

Over the last 11 years the share price moved +11,368% while the NIFTY 500 moved +241%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: lowest operating margin in 14 quarters, foreign funds (FIIs) raised their stake for 4 quarters in a row and number of shareholders up 97% in a year.

1. Lowest operating margin in 14 quarters

   Operating margin was -261.1% in the June 2026 quarter, against 8.4% a year earlier.

2. Foreign funds (FIIs) raised their stake for 4 quarters in a row

   From 4.9% to 6.7% of the company by the September 2026 quarter.

3. Number of shareholders up 97% in a year

   25,676 shareholders in the September 2026 quarter, against 13,054 a year earlier.

For April to June 2026 (the quarter ended 30 June 2026), Fischer Medical Ventures reported revenue of ₹0.72 crore, down 84.1% from ₹4.54 crore a year earlier, and a loss of ₹3.50 crore.

Fischer Medical Ventures results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 7 November 2025, about July to September 2025; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Fischer Medical Ventures closed at ₹25.23 on 4 November 2026, down 72.8% from ₹92.70 a year earlier (7 November 2025) and up 167.3% over five years. Its highest weekly close since March 2016 was ₹117.65 on 31 October 2025.

Fischer Medical Ventures share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

396 weekly closes from 16 March 2016 to 4 November 2026.

4 Nov 2026: Fischer Medical Ventures closed at ₹25.23, up 1.9% on the week and down 24.7% on the month. 22 Sep 2026: ex-date for a dividend of ₹0.05 a share.

Earlier

• Results for April to June 2026: Revenue down 84.1% on a year earlier.
• 7 Nov 2025: Fischer Medical Ventures held its results call for July to September 2025.
• 12 Sep 2025: Share split: face value cut from ₹10 to ₹1 a share (ex-date).

Fischer Medical Ventures paid ₹0.05 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.20% at the ₹25.23 close on 4 November 2026. The last was a dividend of ₹0.05 a share, ex-date 22 September 2026.

Fischer Medical Ventures dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Not in its latest year. Fischer Medical Ventures Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 1 of its last 11 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2025, held on 7 November 2025, Fischer Medical Ventures' management spoke about the quarter; the main points are below.

“We are at the forefront of taking advantage of these transformative government programs and are reaping the benefits going forward”on the call for July to September 2025

Source: the call transcript.

From the call for July to September 2025, 7 November 2025. The April to June 2026 results are out since, so this part may be out of date until we update it.

Fischer Medical Ventures is on one of our India lists: Penny stocks.

Fischer Medical Ventures Ltd posted a net loss of ₹3.5 Cr in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY26 year was a loss of ₹10.0 Cr. That loss is 486.1% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier lost ₹0.6 Cr. 6 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was −₹10.0 Cr (−1,100.0% on the year before).

Read this profit with care: at −₹3.5 Cr it is bigger than the quarter's whole revenue of ₹0.7 Cr. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −261.1% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings.

Fischer Medical Ventures Ltd reported ₹0.7 Cr of revenue in the Jun 2026 quarter, −84.1% on the same quarter a year earlier. The last full year, FY26, came in at ₹17.0 Cr. The last four reported quarters add to ₹13.6 Cr.

Revenue is everything the company billed its customers in the period.

A growth rate over several years is not shown, because there are too few years of figures to work one out properly.

FY26 revenue was ₹17.0 Cr, +240.0% on the year before.

Is growth speeding up? Revenue over the last 12 months grew +39.1%, against +8.5% a year over the last 8 quarters (accelerating).

Fischer Medical Ventures Ltd's operating margin was −261.1% in the Jun 2026 quarter, 269.5 percentage points lower than the same quarter a year ago. Across 10 years it has been between −300.0% and 11.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −269.5 percentage points on the year while gross margin changed −24.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Fischer Medical Ventures Ltd's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used ₹3.0 Cr of cash, against −₹10.0 Cr of profit. After ₹11.0 Cr of spending on assets, free cash was −₹14.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Fischer Medical Ventures Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹17.0 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹12.0 Cr on assets over the last 3 years.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Averaged over those years that is 23.5% of FY26 revenue a year.

Spending on assets: ₹12.0 Cr over the last 3 years, against ₹1.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Fischer Medical Ventures Ltd's P/E is 91.6×, in the middle of its own history: higher than 55% of past readings. Its usual P/E (the middle reading) is 47.4×, over 8.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved −1,700.0% while the price moved −72.8%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved +21.7% a year; about −15.5% a year came from earnings growth and about +37.2 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Fischer Medical Ventures Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Fischer Medical Ventures Ltd earned a ROCE of −2% in FY26. That is up from a low of −350% in FY17. Its return on capital used (ROIC) is left out: on sales this small it reads 40%, a number that says nothing useful about the business.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a −58.8% net margin and 0.04× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a −58.8% net margin × 0.04× asset turnover × 1.15× leverage (assets divided by equity) ≈ −2.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

Fischer Medical Ventures Ltd has total debt of ₹107 Cr against shareholder equity of ₹387 Cr as of Jun 2026, so its debt is 0.28× its equity, which is very little. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.